Kevin Outterson, JD, LLM
Professor of Law and N. Neal Pike Scholar
Boston University School of Law
Health and Disability Law

JD, Northwestern University School of Law
LLM, University of Cambridge
BS, Northwestern University

Research interests in pharmaceutical innovation, including the law & economics of antimicrobial resistance.

Professor of Health Law, Ethics & Human Rights
Boston University School of Public Health
Health Law, Policy & Management
Center for Health Law, Ethics & Human Rights

Executive Director of CARB-X
Boston University School of Law
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

CARB-X Global Antibacterial Accelerator
06/01/2022 - 05/31/2027 (PI)
HHS/ASPR/Biomedical Advanced Research and Development Authority

CARB-X Global Antibacterial Accelerator (GAMRIF)
01/01/2023 - 03/31/2027 (Multi-PI)
PI: Kevin Outterson, JD, LLM
Department of Health and Social Care

CARB-X Global Antibacterial Accelerator (NNF)
01/01/2024 - 12/31/2026 (Multi-PI)
PI: Kevin Outterson, JD, LLM
Novo Nordisk Foundation

CARB-X Global Antibacterial Accelerator (BMBF)
01/01/2023 - 12/31/2026 (PI)
The German Federal Ministry of Education and Research

CARB-X Global Antibacterial Accelerator (PHAC2)
05/11/2023 - 03/31/2025 (Multi-PI)
PI: Kevin Outterson, JD, LLM
Public Health Agency of Canada

WT CARB-X PD/Acc Costs Cost-Share
04/01/2017 - 03/31/2025 (PI)
Wellcome Trust

Accelerating the Development of innovative Preventive Approaches to Combat AMR
05/18/2018 - 02/28/2025 (PI)
Bill and Melinda Gates Foundation

CARB-X Global Antibacterial Accelerator (WT)
10/06/2021 - 10/05/2024 (PI)
Wellcome Trust

04/01/2019 - 09/30/2024 (Multi-PI)
PI: Kevin Outterson, JD, LLM
University of Antwerp European Commission

CARB-X Global Antibacterial Accelerator (PHAC)
04/01/2023 - 03/31/2024 (Multi-PI)
PI: Kevin Outterson, JD, LLM
Public Health Agency of Canada

Showing 10 of 16 results. Show All Results


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Madden J, Outterson K. Trends in the global antibiotics market. Nat Rev Drug Discov. 2023 Mar; 22(3):174. PMID: 36792692
  2. Outterson K, Rex JH. Global Pull Incentives for Better Antibacterials: The UK Leads the Way. Appl Health Econ Health Policy. 2023 May; 21(3):361-364. PMID: 36773115; PMCID: PMC10119039; DOI: 10.1007/s40258-023-00793-w;
  3. Outterson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020. Clin Infect Dis. 2022 Apr 09; 74(7):1183-1190. PMID: 34251436; PMCID: PMC8994582; DOI: 10.1093/cid/ciab612;
  4. Weldon I, Liddell K, Van Katwyk SR, Hoffman SJ, Minssen T, Outterson K, Palmer S, Viens AM, Viñuales J. A Pandemic Instrument Can Start Turning Collective Problems into Collective Solutions by Governing the Common-Pool Resource of Antimicrobial Effectiveness. J Law Med Ethics. 2022; 50(S2):17-25. PMID: 36889344; PMCID: PMC10009384; DOI: 10.1017/jme.2022.75;
  5. Van Katwyk SR, Outterson K. Introduction: AMR Belongs in the Pandemic Instrument. J Law Med Ethics. 2022; 50(S2):6-8. PMID: 36889349
  6. Rex JH, Outterson K. Antibacterial R&D at a Crossroads: We've Pushed as Hard as We Can … Now We Need to Start Pulling! Clin Infect Dis. 2021 12 06; 73(11):e4451-e4453. PMID: 32584949
  7. Outterson K. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines. Health Aff (Millwood). 2021 11; 40(11):1758-1765. PMID: 34724432
  8. Nanayakkara AK, Boucher HW, Fowler VG, Jezek A, Outterson K, Greenberg DE. Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward. CA Cancer J Clin. 2021 11; 71(6):488-504. PMID: 34546590
  9. Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? Value Health. 2021 12; 24(12):1828-1834. PMID: 34838281
  10. Kållberg C, Hudson J, Salvesen Blix H, Årdal C, Klein E, Lindbæk M, Outterson K, Røttingen JA, Laxminarayan R. The effect of generic market entry on antibiotic prescriptions in the United States. Nat Commun. 2021 05 18; 12(1):2937. PMID: 34006862; PMCID: PMC8131704; DOI: 10.1038/s41467-021-23049-4;
Showing 10 of 89 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 89 publications over 22 distinct years, with a maximum of 9 publications in 2011


Recent (within 3 months)

The Global Antimicrobial Resistance Diary Puts A Face On Serious Infections

Forbes 5/7/2024

4.95 Million People Die From Treatable Infections Annually. A New Project Tells Their Stories

Forbes 5/7/2024


A superbug killed my daughter at 25. Here's how Congress can save others.

USA Today 11/15/2022

Superbugs are a "second punch" after pandemic

Axios 9/9/2022

Should I Be Worried About Resistance to Antibiotics?

Bloomberg 8/21/2022

Antibiotic-resistant infections could dwarf the COVID-19 pandemic

The Boston Globe 7/18/2022

As Big Pharma loses interest in new antibiotics, infections are only growing stronger

News Medical 7/15/2022

How the pandemic screwed up our antibiotics

Vox 7/14/2022

A Better Way to Fund the Fight Against Superbugs

Bloomberg 5/24/2022

Antimicrobial Resistance: What’s At Stake And What Are We Doing About It?

Health Affairs 3/4/2022

The World’s Next Big Health Emergency Is Already Here

The Washington Post 1/27/2022

Drug-Resistant Superbugs Are Causing More Deaths: What’s Being Done?

Healthline 1/26/2022

VIDEO: Sustainable funding of antibiotic development

Healio 11/11/2021

Pfizer buys Amplyx to expand drug-resistant treatment portfolio

Reuters 4/28/2021

The next pandemic? It may already be upon us

The Guardian 2/15/2021

Biden must act quickly to defeat another pandemic

The Boston Herald 2/14/2021

Push and pull: funding drugs to be used only sparingly

Financial Times 2/9/2021

How a Small Biotech Survives Amid Looming Antibiotic Crisis

TheStreet 10/24/2020

We need new antimicrobials to prevent the next infectious disease crisis

STAT 8/12/2020

How a crumbling antibiotics infrastructure could yield ‘catastrophe’

PBS NewsHours 7/30/2020

Antibiotic pipeline in peril from coronavirus and incentives system

Axios 5/5/2020

Coronavirus lessons for the fight against ‘superbugs’

Financial Times 5/4/2020

New Genomic Tests Aim to Diagnose Deadly Infections Faster

The New York Times 2/24/2020

Antibiotic drug resistance is creating a global crisis, UN report says

Vox 5/7/2019

Antibiotics Aren’t Profitable Enough for Big Pharma to Make More

Bloomberg Businessweek 5/3/2019

Medicare payment rules hinder the fight against superbugs

STAT 4/17/2019

CARB-X to fund antibiotic development initiative

Homeland Preparedness News 2/11/2019

20 new antibiotics in pipeline to fight superbugs

The Times 2/5/2019

Antibiotics May Soon Become Useless. Now What?

Wired 10/12/2018
Contact for Mentoring:

765 Commonwealth Ave
Boston MA 02215
Google Map

Outterson's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People